The effects of hyperbaric oxygen therapy on an experimental cisplatin-induced ototoxicity model

Objectives: This study aims to investigate the protective effect of hyperbaric oxygen therapy HBOT as an antioxidant agent on cisplatin ototoxicity. Materials and Methods: Between June 4th, 2014 and June 13th, 2014, a total of 15 adult female Wistar albino rats were used in this study. The rats were divided into the following groups: Group A comprised of five rats and had prophylactic one course of HBOT before intraperitoneal IP cisplatin injection, followed by two more courses of HBOT. Group B comprised of five rats receiving three cycles of HBOT after 10 mg/kg of IP cisplatin administration. Group C served as the control group, including five rats, and received 10 mg/kg IP cisplatin without any additional treatment. The distortion product otoacoustic emission amplitudes of the rats were obtained before and after the study. Results: Group A and Group C showed a significant decrease in all measurements 4,004 Hz, 4,761 Hz, 5,188 Hz, 5,652 Hz, 6,726 Hz, and 7,996 Hz after cisplatin administration compared to that of baseline measurement. In Group B, a significant decrease was observed in the majority of the measurements, although no significant difference was found in 4,761 Hz. Conclusion: Our study results suggest that HBOT neither provides a protective nor therapeutic effect in a rat cisplatin-ototoxicity model.

Keywords:

Cisplatin ototoxicity distortion product otoacoustic emission, hearing loss, hyperbaric oxygen.,

PDF

___

Kerr AG, Booth JB. Scott-Brown's Otolaryngology. Part 3. London: Butterworth International Editions; 1987. p. 465.
Sakamoto M, Kaga K, Kamio T. Extended high- frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol Head Neck Surg 2000;122:828-33.
Akin Ocal FC, Kesici GG, Gurgen SG, Ocal R, Erbek S. The effect of intratympanic oxytocin treatment on rats exposed to acoustic trauma. J Laryngol Otol 2019;133:466-76.
Bekmez Bilmez ZE, Aydin S, Şanli A, Altintoprak N, Demir MG, Atalay Erdoğan B, et al. Oxytocin as a protective agent in cisplatin-induced ototoxicity. Cancer Chemother Pharmacol 2016;77:875-9.
Cobanoglu HB, Vuralkan E, Arslan A, Mirasoglu B, Toklu AS. Is hyperbaric oxygen therapy effective in cisplatin-induced ototoxicity in rats? Clin Exp Otorhinolaryngol 2019;12:66-71.
Kalcioglu MT, Kizilay A, Gulec M, Karatas E, Iraz M, Akyol O, et al. The protective effect of erdosteine against ototoxicity induced by cisplatin in rats. Eur Arch Otorhinolaryngol 2005;262:856-63.
Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007;15:364-9.
Laurell G, Bagger-Sjöbäck D. Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 1991;20:158-167.
Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004;114:538-42.
Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res 2011;281:28-37.
Stengs CH, Klis SF, Huizing EH, Smoorenburg GF. Protective effects of a neurotrophic ACTH(4-9) analog on cisplatin ototoxicity in relation to the cisplatin dose: an electrocochleographic study in albino guinea pigs. Hear Res 1998;124:108-17.
Rybak LP, Ravi R, Somani SM. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol 1995;26:293-300.
Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000;28:73-80.
Teranishi MA, Nakashima T. Effects of trolox, locally applied on round windows, on cisplatin- induced ototoxicity in guinea pigs. Int J Pediatr Otorhinolaryngol 2003;67:133-9.
Giordano P, Lorito G, Ciorba A, Martini A, Hatzopoulos S. Protection against cisplatin ototoxicity in a Sprague- Dawley rat animal model. Acta Otorhinolaryngol Ital 2006;26:198-207.
Saito T, Zhang ZJ, Manabe, Y, Ohtsubo T, Saito H. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur Arch Otorhinolaryngol 1997;254:281-6.
Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226:157-67.
Juhn SK, Hamaguchi Y, Goycoolea M. Review of round window membrane permeability. Acta Otolaryngol Suppl 1989;457:43-8.
Lundman L, Bagger-Sjöbäck D, Holmquist L, Juhn S. Round window membrane permeability. An in vitro model. Acta Otolaryngol Suppl 1989;457:73-7.
Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 1997;18:559-71.
Yassuda CC, Righetti AE, Cury MC, Hyppolito MA, Oliveira JA, Féres O. The role of hyperbaric oxygen therapy (hot) as an otoprotection agent against cisplatin ototoxicity. Acta Cir Bras 2008;23:72-6.
Amora Lde A, Murashima Ade A, Rossato M, Moreira MB, Hyppolito MÂ, Fagundes DJ. The effects of hyperbaric oxygen therapy upon ototoxic injuries produced by amikacin in guinea pigs. Braz J Otorhinolaryngol 2013;79:342-8.